Peyton Howell

Peyton Howell is Chief Executive Officer of Parexel and a member of the company’s Board of Directors. With more than 30 years of pharmaceutical services and healthcare industry experience, Peyton leads Parexel in accelerating the delivery of life-changing treatments to patients.

Most recently, Peyton served as Chief Operating and Growth Officer, where she was responsible for operational delivery, strategy, and growth. Previously, she held the role of Chief Commercial and Strategy Officer, leading the implementation of Parexel’s patient-focused strategy and launching Parexel Biotech. During her tenure, Peyton has made a significant impact in growing Parexel’s customer relationships, delivering strong growth in gross new business awards during a period of significant change in the life sciences industry.

Prior to joining Parexel, Peyton held senior leadership roles at AmerisourceBergen (now Cencora), a Fortune 20 company, where she served as President of Health Systems and Specialty Care Solutions, a $50 billion business unit. Earlier in her career, she was a founder of Lash Group, growing the organization from an early innovator in patient access services to nearly 5,000 employees, and serving as President for nearly a decade following its acquisition by AmerisourceBergen.

Peyton has been recognized with PharmaVoice’s highest distinction as a Red Jacket honoree, which distinguishes an elite group of leaders viewed as the most inspiring in the life sciences industry. She serves on several Board of Directors including Tandem Diabetes Care (NASDAQ: TNDM), a medical device manufacturer; Catalyst, a global nonprofit accelerating organizational performance and women's progress; and the Association of Clinical Research Organizations (ACRO) where she also served as Chairperson in 2024.

Peyton holds a Master of Healthcare Administration from The Ohio State University and a Bachelor of Arts in Health Communications from the University of Illinois.